Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
Conference Call and Webcast Presentation
Date and Time:
Toll Free: 1-877-407-0792
International: 1-201-689-8263
Conference ID: 13748183
Webcast Presentation: Click here
A replay of the webcast, when available, will be posted to Bionomics’ website Events page under the Investors section.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Company Secretary CoSec@bionomics.com.au | Investor Relations kgardner@lifesciadvisors.com | Investor Relations ccalabrese@lifesciadvisors.com |
About
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside
Source: Bionomics Ltd